Xencor Inc 8-K

What Happened
Xencor, Inc. filed a Form 8-K reporting a May 5, 2026 conference call and presentation about data presented at Digestive Disease Week (DDW) 2026. The company made presentation materials available on its website and furnished them as Exhibit 99.1 to the 8-K; the presentation is current as of May 5, 2026. Separately, on May 4, 2026 Xencor issued a press release with final results from the Phase 1 study of XmAb942 in healthy participants and the preclinical characterization of XmAb412, furnished as Exhibit 99.2.

Key Details

• Xencor held a conference call on May 5, 2026 to discuss DDW 2026 presentations and its TL1A portfolio.
• Presentation materials (Exhibit 99.1) and a May 4, 2026 press release (Exhibit 99.2) were furnished with the 8-K.
• The press release includes final Phase 1 study results for XmAb942 in healthy participants and preclinical data on XmAb412.
• The company notes presentation materials on its website are not part of the filing and the presentation is current as of May 5, 2026.

Why It Matters
This filing updates investors on clinical and preclinical progress for Xencor’s programs: final Phase 1 data for XmAb942 (healthy volunteers) and preclinical characterization of XmAb412. Those data points are material for assessing the programs’ development timelines and potential next steps (e.g., further clinical studies). The disclosure is informational — the 8-K does not report financial results, management changes, or definitive regulatory decisions.